The Noradrenergic System in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Nowadays it is well accepted that in Parkinson's disease (PD), the neurodegenerative process occurs in stages and that damage to other areas precedes the neuronal loss in the substantia nigra pars compacta, which is considered a pathophysiological hallmark of PD. This heterogeneous and progressive neurodegeneration may explain the diverse symptomatology of the disease, including motor and non-motor alterations. In PD, one of the first areas undergoing degeneration is the locus coeruleus (LC). This noradrenergic nucleus provides extensive innervation throughout the brain and plays a fundamental neuromodulator role, participating in stress responses, emotional memory, and control of motor, sensory, and autonomic functions. Early in the disease, LC neurons suffer modifications that can condition the effectiveness of pharmacological treatments, and importantly, can lead to the appearance of common non-motor symptomatology. The noradrenergic system also exerts anti-inflammatory and neuroprotective effect on the dopaminergic degeneration and noradrenergic damage can consequently condition the progress of the disease. From the pharmacological point of view, it is also important to understand how the noradrenergic system performs in PD, since noradrenergic medication is often used in these patients, and drug interactions can take place when combining them with the gold standard drug therapy in PD, L-3,4-dihydroxyphenylalanine (L-DOPA). This review provides an overview about the functional status of the noradrenergic system in PD and its contribution to the efficacy of pharmacological-based treatments. Based on preclinical and clinical publications, a special attention will be dedicated to the most prevalent non-motor symptoms of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Although historically the hallmark of the disease has been focused on the degeneration of the substantia nigra pars compacta (SNc), it is now well accepted that the spread of a-synuclein in the brain occurs in stages and that damage to other areas precedes the degeneration of SNc neurons, affecting glutamatergic, nora…”
BackgroundStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 1×
“According to Braak’s theory (Braak et al., 2004), the first asynuclein aggregates in the central nervous system appear in the anterior olfactory structures and the dorsal motor nucleus of the vagus nerve, following by lower raphe system and the locus coeruleus (LC) in stage 2.”
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Aston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“…preclinical models have demonstrated the implication of the LC in arousal, cognition, anxiety, depression, pain, attention, and locomotor control (Aston-Jones and Bloom, 1981; Carter et al., 2010; Curtis et al., 2012; Sara and Bouret, 2012; Chandler et al., 2014; McCall April 2020 | Volume 11 |…”
BackgroundKim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397 · cited 1×
“Indeed, recent publications have suggested that the a-synuclein pathology begins in the gut and travels via the vagal nerve up to the brain where it spreads following the six stages defined by Braak and colleagues (Ulusoy et al., 2013; Kim et al., 2019).”
BackgroundNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Orienting and reorienting: the locus coeruleus mediates cognition through arousal
Sara, S. J., & Bouret, S. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.011 · Cited by 1,056
Locus coeruleus and dopaminergic consolidation of everyday memory
Takeuchi, T., Duszkiewicz, A. J., Sonneborn, A., Spooner, P. A., Yamasaki, M., Watanabe, M., Smith, C. C., Fernández, G., Deisseroth, K., Greene, R. W., et al. (2016) · Nature · doi:10.1038/nature19325 · Cited by 827
Cited by
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Algaidi, S. A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149461 · Cited by 40
Metadata
- Authors
- Paredes-Rodriguez, E., Vegas-Suarez, S., Morera-Herreras, T., De Deurwaerdere, P., & Miguelez, C.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-08
- Volume
- 11
- Pages
- 435-435
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3015663834
- Cited by
- 162
- References
- 23
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Noradrenergic System in Parkinson’s Disease. https://app.cochat.ai/papers/10.3389/fphar.2020.00435
- The paper
- Paredes-Rodriguez, E., Vegas-Suarez, S., Morera-Herreras, T., De Deurwaerdere, P., & Miguelez, C. (2020). The Noradrenergic System in Parkinson’s Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2020.00435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.